Mingnan Chen portrait
  • Member, Nano Institute of Utah
  • Assistant Professor, Pharmaceutical Chemistry
  • Assistant Professor, Pharmaceutical Chemistry
  • Associate Professor, Pharmaceutical Chemistry
  • Member, Huntsman Cancer Institute
801-581-7616

Research Keywords

  • Autoimmune Diseases
  • Vaccines
  • Immune-Tolerant Biomaterials
  • Drug Delivery
  • Biomaterials
  • Metastasis

Presentations

  • Mingnan Chen. Selective supression of autoimmunity through a PD-1-targeted protein toxin. Molecular Engineering & Sciences Institute. University of Washington. Seattle, WA. , , 2018.
  • Mingnan Chen. Season Immunity with Protein Therapeutics. The Second Oversea Young Scholars Forum of Tongji Hospital. Wuhan, Hubei Province, China. , , 2018.
  • Mingnan Chen. PD-1 positive cells and type-1 diabetes. University of Utah Seminars in Metabolism. Salt Lake City, UT, USA. , , 2018.
  • Mingnan Chen. Modulations of the PD-1 immune checkpoint – from cancer to autoimmunity, and back to cancer. University of California at Davis Comprehensive Cancer Center. Sacramento, CA, USA. , , 2018.
  • Mingnan Chen. Protein Engineering to Modulate Autoimmunity and Cancer Immunity. University of Texas at Austin College of Pharmacy, Austin, TX, USA. , , 2018.
  • Mingnan Chen. Development of protein tools to harness the PD-1 immune checkpoint. University of Emory Winship Cancer Institute, Atlanta, GA, USA. , , 2018.
  • Mingnan Chen. Protein engineering to modulate autoimmunity. University of Georgia Department of Chemistry. Athens, GA, USA. , , 2018.
  • Mingnan Chen. Seizing back the PD-1 immune checkpoint - protein engineering to improve immunotherapies for autoimmune diseases and cancer. John Hopkins University Department of Chemical and Biomolecular Engineering, Baltimore, MD, USA. , , 2017.
  • Mingnan Chen. Seizing back the PD-1 immune checkpoint - protein engineering to improve immunotherapies for cancer and autoimmune diseases. UNC-Chapel Hill and NC State University, Chapel Hill, NC, USA. , , 2017.
  • Mingnan Chen. Cancer immunotherapy: past, future, and now. The "Hainan-Utah International Center for Translational Nanomedicine" program. The First Affiliated Hospital of Hainan Medical University. Haikou, Hainan, China. , , 2016.
  • Mingnan Chen. Nano immunotherapy for cancer--engineering iTEP nanoparticle vaccines. The Affiliated Hospital of Hainan Medical College and the Exchange Program for High-End Foreign Experts. Haikou City, Hainan Province, China. , , 2015.
  • Mingnan Chen. Immune-tolerant elastin-like polypeptide (iTEP) -A “bilingual” material that energizes vaccines and cancer stem cell therapy. BYU Idaho Department of Chemistry. Rexberg, ID. , , 2015.
  • Mingnan Chen. Immune-tolerant elastin-like polypeptide (iTEP) nanoparticle: a “bilingual” nanocarrier that energizes cancer stem cell-targeted therapy. The Affiliated Hospital of Hainan Medical College and the Exchange Program for High-End Foreign Experts. Haikou, Hainan, China. , , 2014.
  • Mingnan Chen. Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles. The Annual NCI Alliance for Nanotechnology in Cancer Investigators’ Meeting. Rockville, MD. , , 2014.
  • Mingnan Chen. A “Bilingual” biomaterial that energizes vaccine and cancer stem cell-targeted therapy. University of North Carolina at Chapel Hill Department of Pharmacology Seminar. Chapel Hill, NC. , , 2014.
  • Mingnan Chen. Immune-tolerant elastin-like polypeptide (iTEP) – A “bilingual” biomaterial and its application. Utah Nano Institute NTP Orientation. Salt Lake City, UT. , , 2014.
  • Mingnan Chen. Dual functions of salinomycin in a drug delivery system targeting cancer stem cells. The Annual NCI Alliance for Nanotechnology in Cancer Investigators’ Meeting. Bethesda, MD. , , 2013.
  • Mingnan Chen. Engineering nanocarriers that target metastasis-initiating Cells. The Annual NCI Alliance for Nanotechnology in Cancer Investigators’ Meeting, Houston, TX. , , 2012.
  • Mingnan Chen. Engineering elastin-like polypeptide carriers for cancer chemotherapeutics and peptide vaccines. The University of Utah Pharmacology & Toxicology Department Seminar Series. Salt Lake City, UT. , , 2012.
  • Mingnan Chen. Developing nanocarriers for anti-metastasis therapy and cancer vaccination. The Pancreatic Cancer Research Group (PCRG) monthly meeting. Salt Lake City, UT. , , 2012.
  • Mingnan Chen. Chimeric polypeptide-based nano-carriers for cancer drug delivery. Distinguished Lecture Series: University of South Florida Nanomedicine Research Center & the Division of Translational Medicine. Tampa, FL. , , 2010.
  • Mingnan Chen. Selective suppression of autoimmunity through depletion of programmed death-1 (PD-1)-positive cells. 5th Annual Biopharmaceutics Research and Development Symposium (BRDS). University of Nebraska Medical Center, Omaha, NE. September 5-6, 2018. , , 2018.
  • Mingnan Chen. Protein engineering to modulate the immunostasis mediated by the PD-1 immune checkpoint.256th ACS National Meeting in Boston, MA, August 19-23, 2018. , , 2018.
  • Mingnan Chen. Direct CTL epitope-loading to dendritic cells. Huntsman Cancer Institute Third Annual Cancer Immunotherapy Conference 2018. Salt Lake City, UT, USA. , , 2018.
  • Mingnan Chen. iTEP Fusions, A Drug Delivery Toolbox for Cancer Immunotherapy. Huntsman Cancer Institute Second Annual Cancer Immunotherapy Conference 2017. Salt Lake City, Utah. , , 2017.
  • Immune-tolerant elastin-like polypeptide (iTEP) nanoparticles promote peptide vaccine presentation by dendritic cells. Virus-Like Particle and Nano-Particle Vaccines 2014. San Diego, CA. , , 2014.
  • Biomaterials 2010 Annual Meeting and Exposition: Where Materials Meet Biology. Title: Chimeric polypeptide-doxorubicin conjugates self-assemble into nanoparticles and abolish tumors after a single injection. Seattle, WA. , , 2010.
  • Biomedical Engineering Society 2010 Annual Meeting: Engineering New Frontiers in Medicine and Biology. Title: Chimeric polypeptide-doxorubicin nanoparticle self-assembly abolishes tumors after a single injection. Austin, TX. , , 2010.
  • Chen M, Dong S, Zhao P, Cho S, Wang P, Xu T, Parent K. Immune-tolerant elastin-like polypeptide (iTEP) -A biocompatible and thermo-responsive biomaterial and its applications in vaccination and cancer chemotherapy. Poster session presented at 2016 LS Skaggs Biomedical Research Symposium, Pocatello. Poster, Presented, 2016.
  • Dong S, Cho S, Parent K, Chen M. An immune-tolerant elastin-like polypeptide (iTEP) nanoparticle that improve the potency of cytotoxic T lymphocyte vaccines. Poster session presented at Immunology, Inflammation and Infectious Diseases Summer Symposium, Midway, UT. Poster, Presented, 2015.
  • Dong S, Cho S, Parent K, Chen M. An immune-tolerant elastin-like polypeptide (iTEP) nanoparticle that improve the potency of cytotoxic T lymphocyte vaccines. Poster session presented at Cancer Nanotechnology Gordon Research Conference, West Dover, VT. Poster, Presented, 2015.
  • Chen M, Dong S, Cho S, Parent K.. Immune-tolerant elastin-like polypeptide (iTEP)-based CTL vaccine carriers. Poster session presented at 17th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT. Poster, Presented, 2015.
  • Zhao P, Xia G, Dong S, Jiang Z, Chen M. iTEP nanoparticle-delivered salinomycin displays an enhanced anti-tumor and anti-metastasis efficiency in orthotopic breast tumors. Poster session presented at 17th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT. Poster, Presented, 2015.
  • Zhao P, Dong S, Chen M. iTEP nanoparticles promotes Salinomycin’s inhibition to breast cancer stem cells (CSCs). Poster session presented at 2014 AAPS Annual Meeting and Exposition., San Diego, CA. Poster, Presented, 2014.
  • Dong S, Cho S, Chen M. Immune-tolerant elastin-like polypeptide (iTEP) nanoparticles promote peptide vaccine presentation by dendritic cells. Poster session presented at Cancer Investigator's meeting, Rockville, MD. Poster, Presented, 2014.
  • Dong S, Cho S, Chen M. Immune-tolerant elastin-like polypeptide (iTEP) nanoparticles promote peptide vaccine presentation by dendritic cells. Poster session presented at AACR Annual Meeting 2014, San Diego, CA. Poster, Presented, 2014.
  • Zhao P, Dong S, Chen M. Dual functions of Salinomycin in a drug delivery system targeting cancer stem cells. Poster session presented at The 10th Anniversary-Nanotechnology Conference & Exhibition, Salt Lake City, UT. Poster, Presented, 2013.
  • Chen M. Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles. Poster session presented at The Annual NCI Alliance for Nanotechnology in Cancer Investigators’ Meeting, Boston, MA. Poster, Presented, 2011.
  • Chen M. Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles. Poster session presented at The Kick-off Meeting of the NCI Alliance for Nanotechnology in Cancer, Bethesda, MD. Poster, Presented, 2010.
  • Chen M, MacKay JM, McDaniel JR, Liu W, Simnick A, Chilkoti A. Polypeptide-Doxorubicin Nanoparticle Self-Assembly Abolish Tumors after A Single Injection. Poster session presented at 2010 BMES Annual Meeting, Austin, TX. Poster, Presented, 2010.
  • Chen M, MacKay JM, McDaniel JR. Liu W, Simnick A, Chilkoti A. A single dose of chimeric polypeptide-doxorubicin conjugate leads to complete regression of murine tumors. Poster session presented at 2010 Kewaunee Lecture, Duke University, Durham, NC. Poster, Presented, 2010.
  • Chen M, MacKay JM, McDaniel JR, Liu W, Simnick A, and Chilkoti A. A single dose of chimeric polypeptide-doxorubicin conjugate leads to complete regression of murine tumors. Poster session presented at 2009 Cancer Center Annual Meeting, Duke University, Durham, NC. Poster, Presented, 2009.
  • Chen M, MacKay JM, McDaniel JR, Liu W. Simnick A, Chilkoti A. A single dose of chimeric polypeptide-doxorubicin conjugate leads to complete regression of murine tumor. Poster session presented at The 2009 Center for Biologically Inspired Materials and Material System Retreat, Duke University, Beaufort, NC. Poster, Presented, 2009.
  • Chen M, Bouvier M. A molecular understanding of tapasin: a critical endoplasmic reticulum (ER)-resident protein in the MHC class I antigen presentation pathway. Poster session presented at A molecular understanding of tapasin: a critical endoplasmic reticulum (ER)-resident protein in the MHC class I antigen presentation pathway, Boston, MA. Poster, Presented, 2007.
  • Chen M, Tan Y, Li Z, and Bouvier M. Biochemical and structural characterization of class I accessory proteins. Poster session presented at Keystone Symposia – Cell Biology of the Immune Response, Keystone, CO. Poster, Presented, 2003.
  • Chen M, Stafford, W.F., Diedrich, G., Khan, A., and Bouvier, M. A characterization of lumenal region of human tapasin reveals the presence of two structural domains. Poster session presented at FASEB Summer Research Conference - Protein Folding in the Cell, Saxtons River, VT. Poster, Presented, 2002.

Languages

  • English, Fluent.
  • Chinese, Fluent.

Publications

  • Wang P, Dong S, Zhao P, He X, Chen M (date unknown). Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo. Vol. 182, 92-103. Accepted, .
  • Zhao P, Dong S, Bhattacharyya J, Chen M (date unknown). iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Accepted, .
  • MacKay JA*, Chen M,* Liu W, McDaniel J, Simnick A, and Chilkoti A (date unknown). Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumors after a single injection. Vol. 8, 993-999. Accepted, .
  • Sadegh-Nasseri S, Chen M, Narayan K, and Bouvier M (date unknown). The convergent roles of tapasin and HLA-DM in antigen presentation. Vol. 29, 141-147. Accepted, .
  • Chen M, Bouvier M (date unknown). Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. Recommended as a “Must Read” paper by Faculty of 1000 Biology. Vol. 26, 1681-1690. Accepted, .
  • Zhao P, Wang P, Dong S, He X, Zhou Z, Cao Y, Yagita H, He X, Fisher SJ, Fujinami RS, Chen M (date unknown). Depletion of PD-1-positive cells ameliorates autoimmune disease. Accepted, .